{
 "episode_id": "huberman-lab-2026-06-04-essentials-psychedelics-neurostimulation-for-brain-rewiring-",
 "title": "Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams",
 "podcast": "huberman-lab",
 "published_at": "2026-06-04",
 "speakers": [
  "Andrew Huberman",
  "Nolan Williams"
 ],
 "summary": "Stanford neurologist-psychiatrist Dr. Nolan Williams joins Andrew Huberman for a Huberman Lab Essentials episode on rewiring the depressed brain. Williams frames depression as the most disabling condition worldwide — recently added by the American Heart Association as a fourth major risk factor for coronary artery disease — and explains how transcranial magnetic stimulation over the left dorsolateral prefrontal cortex restores that region's governance over the cingulate, a brain-heart circuit he can probe directly via heart-rate deceleration. He argues the serotonin 'chemical imbalance' story (Psychiatry 2.0) is wrong and proposes a circuit-based 'Psychiatry 3.0' in which depression is recalibratable like an arrhythmia, citing his lab's rapid five-day Stanford Neuromodulation Therapy (SAINT/SNT) protocol that compresses seven and a half months of TMS into 50 hours using spaced learning theory, with 60-90% remission. The pair then tour the psychedelic evidence: MDMA producing clinically significant PTSD improvement in about two-thirds of patients, psilocybin helping a third to two-thirds of depressed patients depending on study design, ketamine's short ~1.5-week durability, ibogaine's 24-36 hour 'life review' now being studied in special-operations veterans, and ayahuasca's two-plant pharmacology plus the Brazilian prisoner recidivism study. Williams insists these compounds are not recreational and must stay under strict medical supervision, but says that stripped of their countercultural baggage they could prove to be a breakthrough for psychiatry.",
 "topics": [
  {
   "name": "Depression's scale and the brain-heart connection",
   "timestamp": "0:00",
   "summary": "Williams describes depression as the most disabling condition worldwide, both a risk factor for and an aggravator of other illnesses, and explains his lab's work probing a direct brain-heart circuit: TMS over mood-regulatory regions decelerates the heart rate."
  },
  {
   "name": "How TMS works: restoring prefrontal governance",
   "timestamp": "2:57",
   "summary": "Williams walks through the mechanism — magnetic pulses depolarize neurons in the dorsolateral prefrontal cortex, propagating down to the cingulate, insula, amygdala and ultimately the vagus nerve and heart — and frames depression as the deeper regions governing the prefrontal cortex instead of the reverse."
  },
  {
   "name": "SSRIs, the chemical-imbalance myth, and Psychiatry 3.0",
   "timestamp": "9:48",
   "summary": "Williams says SSRIs clearly work for a subpopulation but not via fixing a serotonin deficit; he traces psychiatry from Freud (1.0) through the chemical imbalance era (2.0) to a circuit-focused 3.0 in which depression is a recalibratable electrophysiological problem."
  },
  {
   "name": "Psychedelic trial results: MDMA, psilocybin, ketamine",
   "timestamp": "16:05",
   "summary": "Discussion of why the brain holds onto maladaptive rules (evolutionary neurobiology, PTSD as battlefield-adaptive) and the clinical numbers: ~two-thirds of PTSD patients improve after one or two MDMA sessions, psilocybin helps a third to two-thirds of depressed patients, and ketamine's effect lasts only about a week and a half per infusion."
  },
  {
   "name": "Neurochemistry of psilocybin and convergent circuitry",
   "timestamp": "21:47",
   "summary": "Williams reviews Nutt and Carhart-Harris's neuroimaging finding that psychedelics decrease overall brain activity while increasing global connectivity, and notes psilocybin produces the same subgenual-cingulate/default-mode-network decoupling his lab sees with effective Stanford Neuromodulation Therapy — a convergent mechanism."
  },
  {
   "name": "Ibogaine: the life review and the veterans study",
   "timestamp": "24:07",
   "summary": "Williams describes ibogaine's 24-36 hour 'life review' ('10 years of psychotherapy in a night'), its cardiac risk and ECG screening, and his lab's first-in-human full neurobiological evaluation in special-operations veterans, who anecdotally report resolution of PTSD symptoms and moral injury."
  },
  {
   "name": "Ayahuasca and the Brazilian prisoner study",
   "timestamp": "30:49",
   "summary": "Williams explains ayahuasca's two-plant chemistry (a reversible MAOI protecting DMT from gut breakdown), evidence of its safety including a study of exposed children, and a Brazilian study in which ayahuasca-exposed prisoners had statistically significantly lower recidivism than controls."
  },
  {
   "name": "Stanford Neuromodulation Therapy (SAINT/SNT)",
   "timestamp": "36:09",
   "summary": "Williams explains how his team used spaced learning theory to compress and intensify TMS — hourly stimulation for 10 hours a day over five days, seven and a half months of dose in a 50-hour block — achieving full remission in 60-90% of patients, with durability the remaining open question."
  }
 ],
 "entities": [
  {
   "name": "Nolan Williams",
   "type": "person",
   "salience": "central",
   "role_in_episode": "Guest; Stanford dual-trained neurologist-psychiatrist behind Stanford Neuromodulation Therapy and the ibogaine veterans research."
  },
  {
   "name": "Andrew Huberman",
   "type": "person",
   "salience": "central",
   "role_in_episode": "Host; frames the questions on depression, psychedelics, and neurostimulation."
  },
  {
   "name": "Depression",
   "type": "concept",
   "salience": "central",
   "role_in_episode": "The central clinical condition — its global burden, circuit basis, and treatment via TMS and psychedelics."
  },
  {
   "name": "Transcranial magnetic stimulation",
   "type": "concept",
   "salience": "central",
   "role_in_episode": "The neurostimulation modality Williams uses to restore prefrontal governance and probe the brain-heart connection."
  },
  {
   "name": "Stanford Neuromodulation Therapy",
   "type": "concept",
   "salience": "central",
   "role_in_episode": "Williams's accelerated five-day TMS protocol (formerly SAINT) built on spaced learning theory, achieving 60-90% remission."
  },
  {
   "name": "SSRIs",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "Discussed as effective for a subpopulation but slow-acting, likely via plasticity rather than fixing a serotonin deficit."
  },
  {
   "name": "Serotonin",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "The neurotransmitter at the heart of the 'chemical imbalance' hypothesis Williams argues against."
  },
  {
   "name": "Psychiatry 3.0",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "Williams's framing of circuit-focused psychiatry, succeeding Freudian (1.0) and chemical-imbalance (2.0) eras."
  },
  {
   "name": "Psilocybin",
   "type": "concept",
   "salience": "central",
   "role_in_episode": "Psychedelic with antidepressant trial data and a connectivity signature converging with SNT's mechanism."
  },
  {
   "name": "MDMA",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "Discussed for its trial results: clinically significant PTSD improvement in about two-thirds of patients."
  },
  {
   "name": "Ketamine",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "Contrasted with psilocybin and MDMA for its short ~1.5-week durability per infusion."
  },
  {
   "name": "Ibogaine",
   "type": "concept",
   "salience": "central",
   "role_in_episode": "The longest-acting, most potent psychedelic Williams knows; subject of his first-in-human study in special-operations veterans."
  },
  {
   "name": "Ayahuasca",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "South American two-plant psychedelic sacrament, discussed for its pharmacology, safety record, and the Brazilian prisoner recidivism study."
  },
  {
   "name": "PTSD",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "Condition framed as evolutionarily adaptive in the battlefield and treated in trials with MDMA and ibogaine."
  },
  {
   "name": "Dorsolateral prefrontal cortex",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "The TMS stimulation target — the brain's 'governor' whose end organ is the heart and whose grip on the cingulate fails in depression."
  },
  {
   "name": "Default mode network",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "Its connectivity with the subgenual anterior cingulate is the convergent change seen after both SNT and psilocybin."
  },
  {
   "name": "Psychedelics",
   "type": "concept",
   "salience": "central",
   "role_in_episode": "The broad class — psilocybin, MDMA, ibogaine, ayahuasca — Williams evaluates as potential breakthrough psychiatric treatments under strict supervision."
  },
  {
   "name": "Space learning theory",
   "type": "concept",
   "salience": "discussed",
   "role_in_episode": "The learning-optimization principle (hourly repetition) Williams used to reorganize TMS dosing into the five-day SNT protocol."
  },
  {
   "name": "American Heart Association",
   "type": "organization",
   "salience": "mentioned",
   "role_in_episode": "Recently added depression as the fourth major risk factor for coronary artery disease."
  },
  {
   "name": "Stanford School of Medicine",
   "type": "organization",
   "salience": "mentioned",
   "role_in_episode": "Home institution of both Huberman and Williams's neuromodulation lab."
  },
  {
   "name": "Navy SEALs",
   "type": "organization",
   "salience": "mentioned",
   "role_in_episode": "Special-operations veterans population in Williams's PTSD and ibogaine work."
  },
  {
   "name": "David Nutt",
   "type": "person",
   "salience": "mentioned",
   "role_in_episode": "Pioneer (with Robin Carhart-Harris) of psychedelic neuroimaging showing decreased brain activity and increased global connectivity."
  },
  {
   "name": "Robin Carhart-Harris",
   "type": "person",
   "salience": "mentioned",
   "role_in_episode": "Pioneer (with David Nutt) of psychedelic neuroimaging showing decreased brain activity and increased global connectivity."
  },
  {
   "name": "MAPS",
   "type": "organization",
   "salience": "mentioned",
   "role_in_episode": "Source of the standard clinical MDMA dose (150-175mg) Huberman cites."
  }
 ],
 "claims": [
  {
   "holder": "Nolan Williams",
   "claim": "The heart is consistently the end organ of the dorsolateral prefrontal cortex — TMS over that mood-regulatory region directly decelerates the heart rate, a finding replicated several times.",
   "stance": "assertion",
   "conviction": 0.8,
   "subjects": [
    "Dorsolateral prefrontal cortex",
    "Transcranial magnetic stimulation",
    "Depression"
   ],
   "timestamp": "2:57",
   "quote": "So the heart very consistently seems to be the end organ of the dorsolateral prefrontal cortex."
  },
  {
   "holder": "Nolan Williams",
   "claim": "In depression the left dorsolateral prefrontal cortex fails to clamp down on the cingulate's conflict-detection output, and TMS exogenously restores that governance — the degree of re-regulation correlates with antidepressant effect.",
   "stance": "assertion",
   "conviction": 0.7,
   "subjects": [
    "Depression",
    "Dorsolateral prefrontal cortex",
    "Transcranial magnetic stimulation"
   ],
   "timestamp": "5:22",
   "quote": "In depression, it looks like the left dorsal lateral does not sufficiently clamp down on it."
  },
  {
   "holder": "Nolan Williams",
   "claim": "SSRIs clearly work for a subpopulation of patients across depression, OCD, anxiety and panic, with many meta-analyses proving it out.",
   "stance": "fact_cited",
   "conviction": 0.9,
   "subjects": [
    "SSRIs",
    "Depression"
   ],
   "timestamp": "9:48",
   "quote": "SSRIs clearly work, you know, many, many meta-analyses kind of proving that out, right?"
  },
  {
   "holder": "Nolan Williams",
   "claim": "The chemical-imbalance theory of depression is wrong — there is no serotonin deficit, and psychiatry has long known this.",
   "stance": "assertion",
   "conviction": 0.9,
   "subjects": [
    "Serotonin",
    "Depression",
    "SSRIs"
   ],
   "timestamp": "9:48",
   "quote": "There's not a deficit of serotonin. We're not born with what people call a chemical imbalance."
  },
  {
   "holder": "Nolan Williams",
   "claim": "SSRIs likely work through brain plasticity effects rather than the serotonin itself, since they do not work the day you start taking them.",
   "stance": "opinion",
   "conviction": 0.6,
   "subjects": [
    "SSRIs",
    "Serotonin"
   ],
   "timestamp": "9:48",
   "quote": "it's much more likely that it may have some brain plasticity effects"
  },
  {
   "holder": "Nolan Williams",
   "claim": "His lab's TMS results push back on the serotonin hypothesis as the center of depression, because rapid remission happens with no serotonin given.",
   "stance": "assertion",
   "conviction": 0.8,
   "subjects": [
    "Serotonin",
    "Transcranial magnetic stimulation",
    "Depression"
   ],
   "timestamp": "9:48",
   "quote": "So our work actually kind of pushes back on this serotonin hypothesis as being kind of the center of depression, because it says, look, we're not giving anybody any serotonin."
  },
  {
   "holder": "Nolan Williams",
   "claim": "Psychiatry 3.0 — focusing on the circuit rather than missing chemicals or childhood experiences — reframes psychiatric illness as highly correctable electrophysiology, which is empowering for patients.",
   "stance": "opinion",
   "conviction": 0.85,
   "subjects": [
    "Psychiatry 3.0",
    "Depression"
   ],
   "timestamp": "9:48",
   "quote": "And so it refocuses the story on something that's highly correctable, and it's basically electrophysiology, and it's basically kind of recalibrating a circuit that is recalibrate-able."
  },
  {
   "holder": "Nolan Williams",
   "claim": "PTSD symptoms persist because they were evolutionarily adaptive — the same hypervigilance that is maladaptive at home is highly adaptive on the battlefield.",
   "stance": "opinion",
   "conviction": 0.7,
   "subjects": [
    "PTSD"
   ],
   "timestamp": "16:05",
   "quote": "But if you put them back in the battlefield, highly adaptive, that's highly adaptive, right?"
  },
  {
   "holder": "Nolan Williams",
   "claim": "The psilocybin story for depression and the MDMA story for PTSD are more interesting than ketamine because their effects appear far more durable than ketamine's ~1.5 weeks per infusion.",
   "stance": "opinion",
   "conviction": 0.7,
   "subjects": [
    "Psilocybin",
    "MDMA",
    "Ketamine"
   ],
   "timestamp": "19:42",
   "quote": "that's where I think the psilocybin story for depression and the MDMA story for PTSD seem more interesting to me."
  },
  {
   "holder": "Nolan Williams",
   "claim": "Psilocybin and Stanford Neuromodulation Therapy share a convergent mechanism — both downregulate connectivity between the subgenual anterior cingulate and the default mode network, unpairing the negatively-valenced mood system from self-representation.",
   "stance": "assertion",
   "conviction": 0.7,
   "subjects": [
    "Psilocybin",
    "Stanford Neuromodulation Therapy",
    "Default mode network"
   ],
   "timestamp": "21:47",
   "quote": "And you see that same connectivity change occur post psilocybin, suggesting there's a convergent mechanism."
  },
  {
   "holder": "Nolan Williams",
   "claim": "Ibogaine is seemingly the most potent and powerful psychedelic but also the riskiest because of its cardiac effect, which is why it has been studied so little.",
   "stance": "opinion",
   "conviction": 0.65,
   "subjects": [
    "Ibogaine"
   ],
   "timestamp": "25:14",
   "quote": "Ibogaine is kind of the both seemingly the most potent and most and most seemingly to me at least most powerful psychedelic, but the one that has the most risk to because it has a cardiac effect."
  },
  {
   "holder": "Nolan Williams",
   "claim": "Ibogaine's cardiac risk can be substantially reduced by screening people out based on their electrocardiogram.",
   "stance": "assertion",
   "conviction": 0.65,
   "subjects": [
    "Ibogaine"
   ],
   "timestamp": "25:14",
   "quote": "It seems to be that you can screen people out that have risk off of their electrocardiogram and reduce the risk quite a bit."
  },
  {
   "holder": "Nolan Williams",
   "claim": "Psychedelics are too powerful to be recreational drugs and must remain under very strict medical supervision — the idea of them going outside it is preposterous given even SSRIs require weekly physician evaluation.",
   "stance": "opinion",
   "conviction": 0.9,
   "subjects": [
    "Psychedelics"
   ],
   "timestamp": "26:46",
   "quote": "They're really too powerful to be used in the context of recreation because they can put you into these states."
  },
  {
   "holder": "Nolan Williams",
   "claim": "The old once-daily six-week TMS protocol failed to exploit spaced learning theory, making it far less potent than it could be.",
   "stance": "assertion",
   "conviction": 0.85,
   "subjects": [
    "Transcranial magnetic stimulation",
    "Stanford Neuromodulation Therapy",
    "Space learning theory"
   ],
   "timestamp": "36:09",
   "quote": "What we found was is that the old way of doing TMS, this idea of just doing it once a day, every day, five days a week for six weeks, didn't utilize the space learning theory."
  },
  {
   "holder": "Nolan Williams",
   "claim": "Conventional TMS has been underdosed — extending treatment from six weeks to months three through five kept improving more patients, so SNT delivers five times the normal dose.",
   "stance": "assertion",
   "conviction": 0.8,
   "subjects": [
    "Transcranial magnetic stimulation",
    "Stanford Neuromodulation Therapy"
   ],
   "timestamp": "36:09",
   "quote": "what we also figured out is that people were under dosing TMS because if you just keep going after six weeks out to month three, four, five, more and more people got better."
  }
 ],
 "predictions": [
  {
   "holder": "Nolan Williams",
   "prediction": "If rigorous trials prove psychedelics' therapeutic effect, they will be seen as a huge breakthrough in psychiatry — combining what SSRIs and psychotherapy do in a single substance.",
   "timeframe": "unspecified",
   "subjects": [
    "Psychedelics",
    "Psychiatry 3.0"
   ],
   "timestamp": "26:46",
   "quote": "But the hypothesis is if it is true, then it's very likely that this will be seen as a breakthrough because it allows you to do these sorts of things that you can't do with normal waking consciousness."
  }
 ],
 "facts": [
  {
   "statement": "Depression is the most disabling condition worldwide.",
   "subjects": [
    "Depression"
   ],
   "timestamp": "0:56",
   "quote": "Depression is the most disabling condition worldwide.",
   "source": "Nolan Williams"
  },
  {
   "statement": "The American Heart Association recently added depression as the fourth major risk factor for coronary artery disease, alongside hypertension, hyperlipidemia, and diabetes.",
   "subjects": [
    "Depression",
    "American Heart Association"
   ],
   "timestamp": "0:56",
   "quote": "recently the American Heart Association added depression as the fourth major risk factor for coronary artery disease",
   "source": "Nolan Williams"
  },
  {
   "statement": "The first MDMA trial for PTSD was recently published in Nature Medicine.",
   "subjects": [
    "MDMA",
    "PTSD"
   ],
   "timestamp": "16:05",
   "quote": "the first MDMA trial was published in Nature Medicine recently.",
   "source": "Nolan Williams"
  },
  {
   "statement": "The standard MAPS clinical MDMA dose is 150 to 175 milligrams.",
   "subjects": [
    "MDMA",
    "MAPS"
   ],
   "value": "150-175 mg",
   "timestamp": "18:44",
   "quote": "I think the standard MAPS dose is 150 to 175 milligrams.",
   "source": "Andrew Huberman"
  },
  {
   "statement": "About two-thirds of trauma patients had a clinically significant change in their PTSD after one or two clinical MDMA sessions, with effects lasting years for some in earlier trials.",
   "subjects": [
    "MDMA",
    "PTSD"
   ],
   "value": "~2/3 of patients",
   "timestamp": "19:13",
   "quote": "It's about two-thirds of people had a clinically significant change in their PTSD.",
   "source": "Nolan Williams"
  },
  {
   "statement": "A single ketamine infusion's antidepressant effect lasts on average only about a week and a half.",
   "subjects": [
    "Ketamine",
    "Depression"
   ],
   "value": "~1.5 weeks per infusion",
   "timestamp": "19:22",
   "quote": "In contrast to with ketamine, which only on average lasts about a week and a half for a single infusion.",
   "source": "Nolan Williams"
  },
  {
   "statement": "Psilocybin for depression helped roughly half to two-thirds of patients in open-label studies (depending on treatment resistance) and about a third in blinded trials.",
   "subjects": [
    "Psilocybin",
    "Depression"
   ],
   "value": "~50-66% open label; ~33% blinded",
   "timestamp": "20:06",
   "quote": "in open label studies, it's closer to like half to two thirds of people that ended up getting better depending upon their level of treatment resistance in the blinded trials. It was more like a third or so of people.",
   "source": "Nolan Williams"
  },
  {
   "statement": "Neuroimaging by David Nutt and Robin Carhart-Harris found an overall decrease in brain activity on psychedelics, alongside increased global connectivity.",
   "subjects": [
    "Psychedelics",
    "David Nutt",
    "Robin Carhart-Harris"
   ],
   "timestamp": "21:47",
   "quote": "There's kind of an overall decrease in the level of activity in the brain with psychedelics.",
   "source": "Nolan Williams"
  },
  {
   "statement": "Ibogaine is an alkaloid extracted from iboga tree root bark, typically grown in Gabon, Africa.",
   "subjects": [
    "Ibogaine"
   ],
   "timestamp": "24:07",
   "quote": "Ibogaine is one of the alkaloids that you can extract from a iboga tree root bark that's typically growing in the country of Gabon, Africa.",
   "source": "Nolan Williams"
  },
  {
   "statement": "An ibogaine experience lasts 24 to 36 hours depending on metabolism — the longest-acting psychedelic Williams knows of.",
   "subjects": [
    "Ibogaine"
   ],
   "value": "24-36 hours",
   "timestamp": "25:06",
   "quote": "Depending upon how fast you metabolize it, sometimes 24, sometimes 36 hours, sometimes it can be shorter, but it is a long time.",
   "source": "Nolan Williams"
  },
  {
   "statement": "Williams's lab has run the first-in-human full neurobiological, clinical, and neurocognitive evaluation of ibogaine, in special-operations veterans (former Navy SEALs and Army Rangers).",
   "subjects": [
    "Ibogaine",
    "Navy SEALs",
    "Nolan Williams"
   ],
   "timestamp": "25:14",
   "quote": "we have over the last couple of years been able to do this first in human kind of full neurobiological clinical neurocognitive evaluation of what Ibogaine is doing",
   "source": "Nolan Williams"
  },
  {
   "statement": "The Amazon contains roughly 10,000 to 20,000 plant species, from which ayahuasca's two-plant combination was somehow found.",
   "subjects": [
    "Ayahuasca"
   ],
   "value": "10,000-20,000 plant species",
   "timestamp": "30:49",
   "quote": "there are, as I understand it, 10,000 to 20,000 plant species in the Amazon",
   "source": "Nolan Williams"
  },
  {
   "statement": "Ayahuasca works because a plant-derived reversible monoamine oxidase inhibitor prevents gut breakdown of DMT, letting it cross the blood-brain barrier.",
   "subjects": [
    "Ayahuasca"
   ],
   "timestamp": "31:35",
   "quote": "the reversible monoamine oxidase inhibitor prevents the GI breakdown of the dimethyltryptamine in such a way that it's then allowed to cross the blood-brain barrier and get into the brain",
   "source": "Nolan Williams"
  },
  {
   "statement": "A UCLA Harbor psychiatrist studying ayahuasca found no neurocognitive effects in Amazonian-tribe children exposed to small sacramental doses, nor in adults.",
   "subjects": [
    "Ayahuasca"
   ],
   "timestamp": "31:35",
   "quote": "he's looked at children even that have been exposed to small doses of ayahuasca as a kind of a sacrament within Amazonian tribes and found no neurocognitive effects, no neurocognitive effects in adults",
   "source": "Nolan Williams"
  },
  {
   "statement": "In a Brazilian prison study, prisoners given an ayahuasca session had a statistically significantly lower recidivism rate than the control group given an inert substance.",
   "subjects": [
    "Ayahuasca"
   ],
   "timestamp": "31:35",
   "quote": "the recidivism rate or the return to prison rate in the ayahuasca-exposed individuals was statistically significantly lower than the recidivism rate in the control group",
   "source": "Nolan Williams"
  },
  {
   "statement": "Stanford Neuromodulation Therapy compresses seven and a half months' worth of TMS dose into five days using spaced learning theory.",
   "subjects": [
    "Stanford Neuromodulation Therapy",
    "Transcranial magnetic stimulation",
    "Space learning theory"
   ],
   "value": "7.5 months of dose in 5 days",
   "timestamp": "36:09",
   "quote": "We're going to have seven and a half months worth in five days using space learning theory.",
   "source": "Nolan Williams"
  },
  {
   "statement": "The SNT protocol is stimulation every hour for 10 hours a day across five days — a 50-hour block containing 90 minutes of actual stimulation.",
   "subjects": [
    "Stanford Neuromodulation Therapy"
   ],
   "value": "50-hour block, 90 min stimulation",
   "timestamp": "38:30",
   "quote": "So it's a 50-hour block. It's 90 minutes of actual stimulation, but spread out through the day in the same way of learning.",
   "source": "Nolan Williams"
  },
  {
   "statement": "With SNT, 60 to 90 percent of patients (depending on open-label vs. trial data) go into full mood remission within one to five days, with durability ranging up to four years.",
   "subjects": [
    "Stanford Neuromodulation Therapy",
    "Depression"
   ],
   "value": "60-90% remission",
   "timestamp": "38:30",
   "quote": "somewhere between 60 and 90 percent of the time, they will go into full-on remission in the sense they're totally normal from a mood standpoint at the end of this",
   "source": "Nolan Williams"
  }
 ],
 "notable_quotes": [
  {
   "speaker": "Nolan Williams",
   "timestamp": "5:22",
   "quote": "TMS is almost like exercise for the brain, right?",
   "why": "Crisp framing of neuromodulation as physiologically training a circuit rather than medicating a chemistry."
  },
  {
   "speaker": "Nolan Williams",
   "timestamp": "14:28",
   "quote": "And it just tells us that it's fixable. It's just like an arrhythmia in the heart. It's like a broken leg. We can go in and do something and we can get somebody better.",
   "why": "The core Psychiatry 3.0 message — depression as a correctable circuit problem, not a permanent deficit."
  },
  {
   "speaker": "Nolan Williams",
   "timestamp": "24:07",
   "quote": "They also call it 10 years of psychotherapy in a night.",
   "why": "The memorable shorthand for ibogaine's 24-36 hour life-review experience."
  },
  {
   "speaker": "Nolan Williams",
   "timestamp": "25:14",
   "quote": "Nobody goes to rave on Ibogaine. There's no recreation at all with this.",
   "why": "Punctures the recreational-drug framing that has stalled serious study of the most potent psychedelic."
  },
  {
   "speaker": "Nolan Williams",
   "timestamp": "36:09",
   "quote": "We're going to have seven and a half months worth in five days using space learning theory.",
   "why": "The single compression insight behind SAINT/SNT's rapid-remission results."
  }
 ],
 "extracted_by": "agent",
 "prompt_version": "episode-extract@3",
 "_file": "huberman-lab-2026-06-04-essentials-psychedelics-neurostimulation-for-brain-rewiring-.json"
}